Top Investigators Explore the Complexities of Angiogenesis Cancer Research The targeting of tumor angiogenesis has evolved into one of the most widely pursued therapeutic strategies. However, as of yet, no antiangiogenic agent used as a monotherapy has demonstrated a survival benefit in a randomized Phase III trial. The combination of bev
{{comment.content}}